Kornimate/medical-research-clean huggingface dataset:
dendritic cell immunotherapy for the patients with pancreatic cancer

Conditions: Dendritic Cells; Pancreatic Neoplasms

Summary: the trial evaluates the safety and efficacy of muc-1/wt-1 peptide and/or tumor lysate-pulsed dendritic cell immunotherapy for the patients with pancreatic cancer

the trial evaluates the safety and efficacy of dendritic cell immunotherapy for the patients with pancreatic cancer. dendritic cells are obtained from blood monocytes using standard protocol. two options for dendritic cell priming are used: muc-1/wt-1 peptides for the patients with unresectable tumor and/or tumor lysates for the patients undergoing tumor resection. the dendritic cells are them matured and injected subcutaneous (all patients) and intratumorally (when possible).

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed pancreatic cancer (adenocarcinoma); * hla-a2 expression by tumor cells; * wt-1/muc-1 expression by tumor cells. exclusion criteria: * refuse of patient to participate in the trial; * pregnancy/lactation; * intercurrent severe chronic diseases; * hiv, hepatites b/c; * active tuberculosis; * alcohol use disorder/drug addiction.

Keywords: dendritic cells, pancreatic cancer, immunotherapy
genetics of cardiovascular and neuromuscular disease

Conditions: Cardiomyopathy; Arrhythmia; Muscular Dystrophy

Summary: we are studying the genetics of human cardiovascular and neuromuscular disease. there are many different genetic regions that have been associated with the development of cardiomyopathy. an equal number of genetic regions have been associated with muscular dystrophy and there is overlap because some of the identical genes, when mutated, produce both cardiomyopathy and muscular dystrophy. we are working to identify genes and gene mutations associated with cardiomyopathy, arrhythmias and muscular dystrophy. we propose to screen these samples for mutations in genes known to be involved in these disorders.


Eligibility criteria:
inclusion criteria: * patients of all ages will be considered for the study. in particular, families with more than one affected relative will be sought. exclusion criteria: * subjects without a suspected inherited cardiovascular or neuromuscular disorder will be excluded from this study.

Keywords: cardiomyopathy arrhythmia muscular dystrophy
maximal inspiratory pressure at extubation: relationship with mortality

Conditions: Mechanical Ventilation

Summary: the process of weaning from mechanical ventilation was decided after clinical judgment and weaning predictive index. nevertheless, indexes predicting weaning outcome like maximal inspiratory pressure (mip) are frequently inaccurate. however the long-term involvement of respiratory muscles in critically ill patients has not been established. the objective of this study was to assess the relationship on mip at extubation on one-year mortality in critically ill patients.


Eligibility criteria:
inclusion criteria: * mechanical ventilation at least at 24 hours exclusion criteria: * delirium * cognitive dysfunction * refusal to participate
clinical trial for prostate cancer

Conditions: Prostate Cancer

Summary: phase iii trial using an injectable for treatment of prostate cancer.


Eligibility criteria:

Keywords: prostate cancer psa leuprolide
h-reflex measurement in hemiplegic stroke patients

Conditions: Stroke; Hemiplegia; Spasticity as Sequela of Stroke

Summary: as human beings live longer, geriatric disease develop, one of which was stroke whose prevalence elevated by aging. increased spasticity is a common symptom after stroke and may hinder patient from rehabilitation. the spasticity was evaluated by subjective judgement before. however, in the recent studies, the electrophysiological test, an objective evaluation, showed possibly positive correlation with the spasticity. they compared stroke patients' hemiplegic side with non-hemiplegic side by h/m ratio which showed significant difference. the stroke patients included in studies had stroke onset over 2 years. therefore, investigators wonder if h/m ratio can evaluate spasticity in stroke patients onset within 2 years and if h/m ratio is correlated to spasticity.

stroke is a condition that insufficient brain blood supply due to ischemia or hemorrhage causes brain cell death, which impacts normal function of motor, sensory, and speech, depending on the damaged location. over the world wide, the incidence of stroke is 119 per 100,000 population per year with death rate up to 10-42% in one month after stroke. the survivor developed varying degrees of spasticity up to 42.6%. in the conventional physical examination, modified ashworth scale is used to evaluate spasticity, but its results may be influenced by temperature, joints range of motion, subjective judgement by tester or patient's nervousness. in the previous studies, spasticity between hemiplegic side and sound side showed significant difference in ratio of h/m amplitude, h/m threshold and h/m slope. among them, h/m slope is the most sensitive tool and may be correlated to increased spasticity because h/m slope showed higher value in people with brunnstrom stage iii. however, patients included in previous studies had disease onset over 2 years. the gold recovery stage after stroke is within 6 months. during this time, many methods can be used to reduce spasticity, such as medicine, stretching exercise, and injection. therefore, it is very important whether h/m ratio for spasticity evaluation can be performed in patients with disease onset less than 2 years. in our study, according to onset time, participants will be assigned to three groups: less than 6 months, 6 months to 2 years, and over 2 years. all the participants will accept electrophysiological test over four limbs to collect data of h/m ratio of slope, maximal amplitude and threshold. hemiplegic side will be compared with sound side for significant difference. the relation between h/m ratio and modified ashworth scale will also be identified.

Eligibility criteria:
inclusion criteria: * single episode of stroke * single side hemiplegia after stroke exclusion criteria: * other diagnosis of neurovascular disease or major cardiovascular disease * poor cognition * poor cooperation * aphasia * people who can not tolerate the exam

Keywords: h/m slope h/m maximal amplitude h/m threshold stroke spasticity
the prevention of myocardial enlargement and dilatation post myocardial infarction study

Conditions: Post Myocardial Infarction

Summary: this study is designed to evaluate the effect of pacing on post-mi patients.


Eligibility criteria:
inclusion criteria: * age 18 or above, or of legal age to give informed consent specific to state and national law * willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center and at the intervals defined by this protocol * patient has had a clinically documented anterior myocardial infarction which occurred within the last 14 days * measured peak ck \> 2000 mu/ml within 72 hours of mi. * qrs duration \< 120 ms measured by 12-lead ecg at any time after most recent mi exclusion criteria: * patient has atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) or persistent (i.e., can be terminated with medical intervention, but does not terminate spontaneously) at time of enrollment * patient is in cardiogenic shock defined by systolic blood pressure \< 90 mmhg and on pressor/inotrope medications at time of potential enrollment * patient has 2 or 3 degree heart block at time of potential enrollment * patient has undergone or is scheduled for a coronary artery bypass graft procedure, 30 days before or 30 days after date of potential enrollment * patient has a known life expectancy of less than 6 months due to non cardiac causes * patient has marked renal dysfunction defined as creatinine \> 2.5 mg/dl at time of enrollment * patient enrolled in any concurrent study that may confound the results of the study * patient is in class iv heart failure * patient is on the heart transplant list * patient already has an implanted pacemaker, icd, or crt device * patient is pregnant or plans to be pregnant during the course of the study * both

Keywords: pacing
short-course rifamycin-based regimens for latent tuberculosis in patients with end-stage kidney disease

Conditions: Latent Tuberculosis; Kidney Failure

Summary: objective to determine if treatment completion with a 4-month rifampin (4r) or 3-month rifapentine (p) + isoniazid (h) weekly for 12 weeks (3hp) regimens is better than with a 3-month (3hr) regimen for treatment of latent tuberculosis (tb) infection (ltbi) in patients with end stage kidney disease. methods design: multicenter, prospective, parallel-group, open-label, controlled clinical trial. study population: all adult patients with eskd in who treatment for ltbi is prescribed at 7 hospitals. interventions: patients who accept participation, will be randomly assigned to one of the 3 arms: 3hr (control) (90 doses), 4r (120 doses) or 3hp (12 doses). outcome: proportion of participants who discontinue permanently the assigned treatment. follow-up: periodic assessment for permanent or temporary discontinuation, and adverse events of the assigned treatment. sample size: 225 subjects (75 per arm) will be needed to demonstrate, if exists, a 0.16 decrease in permanent discontinuation rates in the experimental arms (4r and 3hp) with respect to the control arm (3hr), with α= 0.025, β= 0.20, and 5% expected losses, and assuming a 0.25 proportion of permanent discontinuation in the control.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. stage 5 kidney disease (glomerular filtrate rate \<15 ml/minute or under substitutive renal therapy 3. informed written consent exclusion criteria: 1. prior allergy/intolerance to rifamycins or isoniazid 2. pregnancy or breastfeeding 3. pre-treatment transaminases (alt and/or ast) \>5-fold of normality titer 4. concomitant drugs contraindicated with rifamycins 5. having received rifamycins or isoniazid within the two previous weeks 6. weigh \<32 kgs 7. inability to understand the nature of the study or to give written consent

Keywords: tuberculosis rifamycins rifampicin rifapentine kidney failure
simulator of pompage technique for physiotherapists

Conditions: Musculoskeletal Pain; Contracture

Summary: parameterize the pompage technique with an anatomical model cervical region to simulate specific procedures. quantify the times, displacements, and facilitate the training of students and professional of physical therapy.

manual techniques are taught and trained with practical demonstration without technology support to measure them, so they are difficult to reproduce. this difficulty increases in pompage technique because the student is not able to estimate the displacement on the skin. in this research, to parameterize and train the technique was developed and validated an anatomical model of the cervical region, with silicone and latex rubber. the anatomical model simulates the soft tissues and a plastic resin structure represents the cervical spine bone. an optical sensor was used to measure the displacements performed on simulated skin versus time. the likert scale was used for assessing the similarity of the anatomical model relative to the size, shape, texture, elasticity and displacement of the skin as well as the curvature of the cervical spine. five experienced professionals (gp) in the technical performed five series of pompage technique. with the mean of data collected were determined benchmarks for technical and implemented in a standard guide to train the volunteers. twenty-six volunteers (ge) with no experience performed the pompage technique, with the anatomical model following the standard guide. a physical therapist (ve) was selected to evaluate the volunteers (ge) before and after training in the simulator.

Eligibility criteria:
inclusion criteria: * no history of cervical trauma (gt and vf) * do not have dermatitis in the cervical region (gt and vf) * recurrent migraines (gt and vf) * no prior knowledge of pompage technique (ge). * minimum 5 years experience of applying the pompage technique (gp and ve). exclusion criteria: * report pain in the cervical region (gt and vf) * irritations in the cervical region (gt and vf)

Keywords: pompage
sleeve gastrectomy as a standard bariatric procedure

Conditions: Postoperative Complications

Summary: this study compared differences in weight loss, comorbidity resolution and complications and reoperations between a recently established sleeve gastrectomy (sg) and prior laparoscopic rox-en-y gastric bypass (rygb).

this retrospective study with prospectively collected registry data presents results from establishment of sg as standard procedure for morbid obesity. our first 368 patients operated with a sg were compared to 647 patients previously operated with a (rygb. perioperative data and results up to 2 years postoperatively regarding weight control, metabolic control as well as complications/reoperations necessary were registered. in summary, a rygb was associated with a longer operation time and higher rates of late complications and reoperations. diabetes resolution was similar in both groups but patients with a rygb had greater weight loss and significant improvement in hypertension and dyslipidemias.

Eligibility criteria:
inclusion criteria: * patients with either a bmi 35 or higher with comorbidity, or patients with a bmi of 40 or more without known comorbidity associated, undergoing a primary laparoscopic bariatric surgery in sundsvall,sweden 2010-01-01 to 2018-06-10. exclusion criteria: * all other patients undergoing a bariatric surgery during this time frame

Keywords: bariatric surgery laparoscopic roux-en-y gastric bypass laparoscopic sleeve gastrectomy morbid obesity weight loss metabolic control metabolic syndrome complication risk
perioperative chemotherapy with herceptin for potentially resectable her-2 positive gastric cancer with liver metastasis

Conditions: HER-2 Positive Gastric Cancer; Liver Metastasis

Summary: stage i：preoperative therapy * capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients with potentially resectable her-2 positive gastric cancer with liver metastasis; stage ii: perioperative therapy * perioperative capecitabine plus oxaliplatin with herceptin is superior to adjuvant capecitabine plus oxaliplatin alone for patients with potentially resectable her-2 positive gastric cancer with liver metastasis;

the investigators assessed whether the addition of a perioperative regimen of xelox regimen with herceptin to improves r0 resection rate and survival among patients with potentially resectable her-2 positive gastric cancer with liver metastasis.

Eligibility criteria:
inclusion criteria: * 1.pathological tissue were gastric cancer by gastric and liver biopsy. 2.immunohistochemistry confirmed her-2 (+)or fish(+). 3.gastric cancer with liver metastasis were not able to resectable lesions. 4.patients•had not received radiotherapy past and not other organ metastasis and peritoneal metastasis. 5.ecog performance status 0-1. 6.inadequate hematopoietic function： hemoglobin≥90g/l; anc≥1,500/mm3;platelet≥100,000/mm3 7.inadequate organ function which is defined as below: total bilirubin≤1.5 pper limit of normal range (uln); alt / ast≤2.5 upper limit of normal range (uln) (≤5.0 x uln if hepatic metastasis); serum creatinine≤1.5 pper limit of normal range (uln), serum albumin≥30g/l. 8.expectancy must be more than 3 months. 9.the random blood or urine pregnancy test in fertile woman must be the negative results in pregnancy test in 7 days. 10.patients for male and female used reliable contraception contraceptive method until the end of study 30 days later. 11.the operation can complete the d2 operation(lnm≥15). 12.lvef≥50% exclusion criteria: * 1. patients with other extrahepatic metastasis include peritoneal metastasis. 3. patients with other malignancy in 5 years. 4. patients with peripheral nerve disease,two hydrogen pyrimidine dehydrogenase( dpd )deficiency,upper digestive tract obstruction or from malabsorption syndrome. 5.patients with hypertension failed to control, active bleeding, 3\~4 proteinuria, heal the wound, romboembolism, heart failure, clinical symptoms of heart disease. 6.patients have obvious peripheral nervous system disorders,mental disorders and disorders of the central nervous system history. 7.patients have history of organ transplantation. 8.patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study. 9.patients combined antitumor drug outside the research program.

Keywords: xelox herceptin potentially resectable gastric cancer
haloperidol and dexamethasone towards postoperative nausea and pain in adult after laparoscopy

Conditions: Laparoscopy; Postoperative Nausea and Vomiting

Summary: this study aim to find out the effectiveness of 1 mg intravenous haloperidol compared to 5 mg intravenous dexamethasone to prevent the occurrence of nausea and vomiting also as pain control in adult patients after laparoscopic surgery.

eighty subjects (n=40 for each group) scheduled for laparoscopic-assisted surgery were enrolled in a randomized double-blind clinical trial. one milligram intravenous haloperidol was given one hour before the end of surgery, while 5 mg intravenous dexamethasone was given right after induction. the occurrence of postoperative nausea and vomiting (ponv) and visual analog scale (vas) pain score were recorded.

Eligibility criteria:
inclusion criteria: * underwent laparoscopic surgery (gynecology, digestive, or urology surgery) * american society of anesthesiologist (asa) physical status 1-3 exclusion criteria: * psychological or neurological disorders (routine haloperidol consumption) * history of allergic reaction to dexamethasone or haloperidol * diabetes mellitus * did not give the consent

Keywords: dexamethasone haloperidol nausea pain vomiting
back pain and male sexual disfunction

Conditions: Marriage, Life Event

Summary: back pain is a common hormonal disorder in men that may affect the phases of male sexual function. the investigators investigated sexual function in male patients with back pain. a total of 54 men with back pain and 27 age matched voluntary healthy men who served as the as control group were evaluated with a detailed medical and sexual history, including a international erectile function index (iefi) questionnaire and the beck depression inventory. serum prolactin, dehydroepiandrosterone sulfate, free testosterone, androstenedione, 17alpha-hydroxyprogesterone, estradiol, free thyroxin and thyrotropin were measured. these variables were compared statistically between the 2 groups.

a total of 54 men with back pain and 27 age matched voluntary healthy men who served as the as control group were evaluated with a detailed medical and sexual history, including a international erectile function index (iefi) questionnaire and the beck depression inventory. serum prolactin, dehydroepiandrosterone sulfate, free testosterone, androstenedione, 17alpha-hydroxyprogesterone, estradiol, free thyroxin and thyrotropin were measured. these variables were compared statistically between the 2 groups.

Eligibility criteria:
inclusion criteria: * male patient with back pain * 20 - 45 years old * active sexual life exclusion criteria: * younger than 20, older than 45 years old

Keywords: sexual life, back pain
itacitinib in combination with erlotinib in non small cell lung cancer patients with epidermal growth factor receptor (egfr) activating mutations

Conditions: Solid Tumors and Hematologic Malignancy; NSCLC (Non-small Cell Lung Carcinoma)

Summary: the purpose of this study is to determine if itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (nsclc) that is stage iiib/stage iv or recurrent whose tumors have egfr activating mutations.

the study consists of an open-label, safety run-in to confirm the safety of itacitinibin combination with erlotinib in subjects with nonsquamous non-small cell lung cancer (nsclc) that is stage iiib, stage iv, or recurrent whose tumors have egfr activating mutations. subjects in the safety run-in will receive open-label itacitinib and erlotinib. in the second part of the study, subjects will be enrolled and randomized to receive erlotinib (open-label) and either itacitinib or placebo in a blinded manner. the dose of itacitinib administered will be determined from the data produced in the safety run-in phase. treatment will consist of repeating 21-day cycles. subjects will take erlotinib tablets daily and itacitinib/placebo will be self-administered daily during the entire cycle.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of nonsquamous nsclc that is stage iiib, stage iv, or recurrent (including stage ii). * documented evidence of an activating mutation in egfr in tumor samples (exon 19 deletions or point mutation l858r in exon 21 or point mutations at codon 719). * a mgps of 1 or 2 as defined below: * criteria: c-reactive protein \>10 mg/l and albumin ≥35 g/l score-1 * criteria: c-reactive protein \>10 mg l and albumin \<35 g/l score-2 * radiographically measurable or evaluable disease. * life expectancy of at least 12 weeks. * eastern cooperative oncology group (ecog) performance status of 0 to 2. * adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit. exclusion criteria: * known presence of the t790m mutation in egfr in tumor samples * candidates for curative radiation therapy or surgery. * previous systemic chemotherapy for advanced disease, including egfr inhibitor therapy, except subjects who received 1 cycle of chemotherapy while waiting to receive egfr results, who may enroll provided that 21 days have elapsed from end of chemotherapy to the day to the baseline radiographic measurement prior to cycle 1 day 1. * distinct or suspected, or history of, pulmonary fibrosis or ild. * current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive indolent or stage i malignancy without sponsor approval.

Keywords: egfr mutation